Methodology

All entries for: Revio Therapeutics LLP

January 15, 2026

Revio Therapeutics LLP

Orphan Drug Designation

treatment of Duchenne muscular dystrophy

Disease Area: Rare Disease
Source
Source
Scroll to Top